Furthermore, efavirenz-inhibited LINE-1 action lowers the levels of recognized cancer genes in breast cancer, such as EGFR (epidermal growth factor receptor) and ERBB4 (erb-B2 receptor tyrosine kinase 4). This evidence concerns the gene EGFR and breast carcinoma.